METHODS

BACKGROUND AND RATIONALE
• Self-monitoring of blood glucose (SMBG) is a costly component of care for diabetes mellitus with potential overuse of strips recently reported for some patients. 1 • In spite of the potential overuse and costs, SMBG is recognized as a core component of effective diabetes self management by the American Diabetes Association (ADA). 2 • However, the evidence base for an effect of SMBG on hemoglobin A1c (HbA1c) in type 1 and type 2 diabetic patients using insulin is often rated as low-level and scarce. 3 • Demonstrating the marginal effect of increased use of blood glucose testing strips on HbA1c control is an important evidence that is currently lacking in the literature.
OBJECTIVES
The objectives of this study were two-fold: 1) To quantify the marginal effect of increased blood glucose testing strip use on HbA1c control among patients with insulin regimen who have at least 1 testing strip claim. 2) To explore whether the marginal effect differs by type 1 versus type 2 diabetes status.
Hypothesis
• The likelihood of achieving glycemic control (HbA1c <8.0) increases with higher rates of SMBG, defined as increased number of blood glucose testing strips fills.
Study Design and Population Selection Criteria
• A retrospective observational study design was used to study patients from Anthem affiliated BCBS (BlueCross and BlueShield) health plans in the United States.
• The following study specific inclusion criteria were applied:
-The earliest blood glucose testing strip fill date during 01/01/2010 and 12/31/2012 with no prior strip fill for 1 year was defined as the index date -Continuous medical and pharmacy enrollment for 1 year pre and 1 year post index date was required. -Patients were required to have an insulin regimen fill 2 (basal, bolus, or pre-mixed) on index date. -Glycemic control is defined as HbA1c <8.0 per NCQA (National Committee for Quality Assurance) and HEDIS (Healthcare Effectiveness Data and Information Set) Comprehensive Diabetes Care guideline standards. The most current HbA1c lab value within 1 year post-index period was used for analysis. -Type 1 or Type 2 diabetes status 2 was assessed from claims data.
• Age and condition specific exclusion criteria were adapted from HEDIS : 
Statistical Analysis
• Log-binomial analysis was used to identify variables that will be part of the marginal effects analysis. The likelihood of glycemic control (HbA1c <8.0) was modeled.
• Average marginal effects (AME) analysis with bootstrapping was used to estimate the likelihood of being on control as the number of testing strip fills increased taking into account age, gender, insulin regimen type, type 1 status, and other characteristics.
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REFERENCES LIMITATIONS
• Pharmacy fill dates neither imply subsequent full utilization of testing strips nor confirm the actual timing of administration. Therefore, patient exposure to testing strip use could be overestimated.
• The claims and laboratory database used for this study comes from a single large US managed care population which may not be representative of all insulin using patients with blood glucose testing use.
• Patients may obtain blood glucose testing strips through other sources than health plan reimbursement (e.g. over-the-counter purchases). We have mitigated this by limiting the study to patients with at least 1 testing strip fill.
CONCLUSIONS
• Controlling for key factors, the likelihood of glycemic control appeared to increase with higher number of blood glucose testing strip fills for diabetic patients on insulin regimen.
• The association between the number of testing strip fills and the likelihood of glycemic control is stronger among type 1 diabetes patients on insulin regimen.
• Patients residing in areas with higher median household income are also more likely to achieve glucose control.
• These findings highlight the importance of efforts to encourage consistent testing strip use among patients on insulin, with potential implications for improved patient outcomes and long term cost savings. • Type 1 patients tend to be younger and more likely to use bolus regimen. Type 1 patients appeared to use testing strips more often and incur the most of out-of-pocket costs for strips. See table 1 and 2 for details.
• Using the AME analysis, each increase in the number of testing strip fills was associated with a 2.5% increase in the likelihood of achieving control (AME: 2.48, 95% C.I.: 2.13-2.85, p<.001). See figure 2 for details.
• The marginal effect between number of strip fills and glycemic control was greater among type 1 patients, with a 3.5% increase in the likelihood of achieving control (AME: 3.46, 95% C.I.: 2.46 -4.45, p<.001). See figure 2 for details.
• About 27% of Type 1 patients had less than 4 blood glucose testing strip fills in a year compared to the 40% for the overall sample. See table 2. 
